Distinguished in Brain Tumor

Darren R. Hargrave

UCL Great Ormond Street Institute For Child Health
London, ENG, GB 
Distinguished in Brain Tumor
UCL Great Ormond Street Institute For Child Health
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Darren Hargrave practices in London, United Kingdom. Mr. Hargrave is rated as a Distinguished expert by MediFind in the treatment of Brain Tumor. His top areas of expertise are Glioma, Gliomatosis Cerebri, Diffuse Midline Glioma H3 K27M-Mutant, and Brain Tumor.

His clinical research consists of co-authoring 145 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 79 articles in the study of Brain Tumor.

Gender
Male

Locations

UCL Great Ormond Street Institute for Child Health
London, ENG, United Kingdom
Other Locations
Derby Rd, Nottingham NG7 2UH, Nottingham, ENG, United Kingdom
Birmingham, ENG, United Kingdom
Great Ormond Street Hospital
Strete, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Enrollment Status: Completed
Publish Date: October 03, 2024
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 1

145 Total Publications

Prognostic factors of early mortality in children and adolescents with relapsed/refractory solid tumors participating in dose-finding trials in the targeted and immune therapies era: An ITCC study.
Prognostic factors of early mortality in children and adolescents with relapsed/refractory solid tumors participating in dose-finding trials in the targeted and immune therapies era: An ITCC study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hargrave's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 24 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile